PharmaMar and Key Oncologics partner to distribute Yondelis drug in South Africa, Namibia and Botswana
PharmaMar y Key Oncologics firman un acuerdo para distribuir el medicamento Yondelis en Sudáfrica, Namibia y Botsuana
Intel ID : 297889
Relevant Documents
| Press Release | 19 May 2020 | PharmaMar_Nota_de_Prensa_2020.pdf | ES |
|
| Intel ID | 297889 | ||
| Value | ND | ||
| Native Currency | Euro (EUR) | ||
|
Financial Data - PharmaMar
(31 Dec 2021) |
Revenue: EUR 234,42m EBITDA: EUR 97,85m Net Debt: EUR 444,07m |
||
| Date |
 |
||
| Country |  |
||
| Geography | |
||
| Subsector (Old TTR Sectors) |
|
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Radar
| Date | Title | Type | Intel Grade | Country | Subsector | ||
|
|
|
|
|
|
|
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.